Open Label Extension Study of Brentuximab Vedotin in Early dcSSc — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc — Stella

Home/Diffuse Cutaneous Systemic Sclerosis/

View on ClinicalTrials.gov

Recruiting

Back to Diffuse Cutaneous Systemic Sclerosis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Canada

Rheumatology Clinic, St. Joseph's Health Care, London, Ontario

Key details

Phase

Safety & dosing

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborators

Seattle Genetics (now a wholly owned subsidiary of Pfizer), Pfizer

Enrollment target

~11 participants

Started

February 2024

Primary completion

February 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.